论文部分内容阅读
目的观察琥珀酸美托洛尔缓释片治疗扩张型心肌病的临床效果。方法选取2015年2月—2016年2月收治的78例扩张型心肌病患者进行研究,随机分为对照组和观察组各39例,对照组给予酒石酸美托洛尔片,起始剂量为每次6.25 mg,每天3次,根据病情后期缓慢增加至每次50 mg,每天3次;观察组采用琥珀酸美托洛尔缓释片治疗,起始剂量为每次11.875 mg,每天1次,根据病情后期缓慢增加至每次190 mg,每天1次。两组均治疗30 m,比较两组临床效果及不良反应发生情况,数据进行统计学处理,P<0.05为差异有统计学意义。结果观察组总有效率92.31%,对照组总有效率69.23%,两组比较差异有统计学意义(χ~2=6.686,P<0.05);观察组不良反应发生率5.12%,对照组为23.08%,两组比较差异有统计学意义(χ~2=5.186,P<0.05)。结论采用琥珀酸美托洛尔缓释片治疗扩张型心肌病,效果显著,不良反应发生率较低。
Objective To observe the clinical effect of metoprolol succinate sustained release tablets in the treatment of dilated cardiomyopathy. Methods A total of 78 patients with dilated cardiomyopathy treated in our hospital from February 2015 to February 2016 were randomly divided into control group and observation group with 39 patients in each group. The control group was given metoprolol tartrate tablets, the starting dose was Times a day 6.25 mg, 3 times a day, according to the late condition slowly increased to 50 mg, 3 times a day; observation group metoprolol succinate sustained-release tablets treatment, the initial dose of 11.875 mg, 1 time per day, According to the late stage of the disease slowly increased to 190 mg once daily. The two groups were treated for 30 m, the clinical effects and adverse reactions were compared between the two groups, the data were statistically analyzed, P <0.05 for the difference was statistically significant. Results The total effective rate was 92.31% in the observation group and 69.23% in the control group, with significant difference between the two groups (χ ~ 2 = 6.686, P <0.05). The incidence of adverse reactions in the observation group was 5.12% and that in the control group was 23.08 %, The difference between the two groups was statistically significant (χ ~ 2 = 5.186, P <0.05). Conclusion Metoprolol succinate sustained release tablets for the treatment of dilated cardiomyopathy, the effect is significant, the incidence of adverse reactions is low.